14 active shortage notices across 7 countries · 2 anticipated.
Last updated 2 Aug 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Canada | high | 2 | 1 Dec 2023 | — | HC |
| United States | high | 2 | 11 Jul 2022 | — | FDA MedWatch |
| Colombia | high |
| 1 |
| 21 Oct 2015 |
| — |
| INVIMA |
| Italy | medium | 3 | 18 May 2026 | 31 Aug 2026 | AIFA |
| Peru | medium | 3 | 1 Jun 2021 | 15 Sept 2026 | DIGEMID |
| Belgium | medium | 2 | 18 Dec 2025 | 2 Nov 2026 | FAMHP |
| Netherlands | medium | 1 | 6 Mar 2026 | — | CBG-MEB |
Yes. As of the latest regulator updates, Tacrolimus has 14 active shortage notices across 7 countries (Canada, United States, Colombia, Italy, Peru, Belgium and more). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Tacrolimus shortages to manufacturing problems, causes not stated by the regulator, regulatory action. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 25 Jul 2024 to 2 Nov 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.